CN104327057A - Poly-substituted indole statin lactone dehydrated compound and use thereof - Google Patents
Poly-substituted indole statin lactone dehydrated compound and use thereof Download PDFInfo
- Publication number
- CN104327057A CN104327057A CN201410553930.XA CN201410553930A CN104327057A CN 104327057 A CN104327057 A CN 104327057A CN 201410553930 A CN201410553930 A CN 201410553930A CN 104327057 A CN104327057 A CN 104327057A
- Authority
- CN
- China
- Prior art keywords
- acid
- compound
- hydroxyl
- propyl
- carbon atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
The invention provides a compound, belonging to the field of medicinal chemistry. A structural formula of the compound is described in the specification. According to a test, the compound has the effects of restraining the activity of HMG-coA reductase, and can be used as a new-generation potential HMG-coA reductase inhibitor.
Description
Technical field
The invention belongs to medicinal chemistry art, particularly relate to a kind of statins, specifically his statin lactone anhydro compounds of a kind of polysubstituted indoles and uses thereof.
Background technology
Hyperlipidemia is the inducement of various cardiovascular and cerebrovascular diseases, population epidemiology investigation shows, for Chinese male crowd, low-density lipoprotein (in blood of human body lipid mostly and albumin bound form lipoprotein and exist) concentration often raises 1mmol/L that Incidence of CHD can be made to rise 36%, and ischemic cerebral apoplexy risk increases by 31%, in risk factors or its direct illness that the world today " three is high " (hyperlipidemia, hypertension, hyperglycemia) is various disease.Various medical science and biological metabolism research prove, 3-hydroxy-3-methyl penta 2 phthalein CoA-reductase (3-Hydroxy-3-methylglutaryl-CoA Reductase in blood of human body in the content of blood fat (lipoprotein) and liver, HMGR) activity has conclusive association: HMGR enzyme is with substrate 3-hydroxy-3-methyl penta 2 phthalein coenzyme A (3-Hydroxy-3-methylglutaryl-CoA, HMG-CoA) relate to the reduction reaction of four transfer transports for twice in conjunction with generation and generate critical materials 3, the 5-dihydroxy-acid of human body lipid synthesis.3-hydroxy-3-methyl penta 2 phthalein CoA-reductase inhibitors (namely commercially available statins) is the main flow blood lipid-lowering medicine that market is sold, be wherein 12,400,000,000 dollars by the atorvastatin calcium preparation of Pfizer Inc.'s development and sale by 2008 annual sales amounts, can be rated as " cookle " in medical history.The type medicine owing to can expose 3,5-identical dihydroxy-acid structures of same HMGR enzyme bound substrates HMG-CoA through metabolism in human body, and its binding ability with HMGR will be far longer than the normal substrate HMG-coA (K that HMG-CoA combines with HMGR simultaneously
mfor the umol/L order of magnitude, and the IC of statins
50at the nmol/L order of magnitude, namely such statins can fight for the active site of HMGR after entering human body, and then stops HMGR with the combination of HMG-coA, namely inhibits HMG-CoA to 3, the conversion of 5-dihydroxy-acid, and then the synthesis that finally inhibit people's body lipid.
Statins has been found to first-generation lovastatin since the U.S. develops list marketing by Merck & Co., Inc. from the mevastatin of its proto-drug the most, and it experienced by natural fermented statin, synthetic statin, third generation superstatin three phases.Along with to the mechanism of action of statins and the research and development that deepens continuously of Computeraided drug design, recognize that introducing fluorine atom has effect in the suitable site of existing statins or its analogue to the HMGR enzyme inhibition activity improving drug molecule or the toxic side effect that reduces medicine.Foreign patent is as US Patent No. 5409820, US4965200, US5622985, US5691173, US20020183527, US4681893, US5354772, USRE37314, US685868, US6465447, US5753675, US5856336, US7022713, US5854259 and Canadian Patent CA1323836, the Chinese patent CN101580497A such as CA2072945, CN101230055A, CN1539417A and document (Science, 2001 (292): 1160-1164) 3S etc. has all directly or indirectly been asserted, 5R-3, 5-dihydroxy-acid structure is the activated necessary structure of this 3-hydroxy-3-methyl penta 2 phthalein CoA-reductase inhibitors (statins) tool, thus the Statins lipidemia medicine gone on the market on the market is all this class formation, existing patent also all remains this must structure.But statins also has untoward reaction, as: hepatopathy, carcinogenic toxicity, muscle side reaction, particularly rhabdomyolysis, just because of the toxic side effect that this is serious, make Cerivastatin (cerivastatin) remove city.
Utilize model prediction result in Computer-Aided Drug Design, the a series of statins derivative containing 2-hexenolactone fragment structure of design and synthesis, through HMGR enzyme inhibition activity experiment test, find that this series compound has the statins same order of same commercial type or the IC of lower quantity
50test value, can be used as lipidemia medicine and uses.
Summary of the invention
For above-mentioned technical problem of the prior art, the invention provides his statin lactone anhydro compounds of a kind of polysubstituted indoles and uses thereof, described this polysubstituted indoles statin derivative and uses thereof will solve Statins derivative of the prior art and have toxic side effect, and the technical problem of the limited efficiency for the treatment of hyperlipidemia.
The invention provides a kind of compound, its structural formula is as follows,
Wherein, R1, R2, R12 is hydrogen, saturated or the unsaturated alkyl of the straight chain of 1-10 carbon atom or cyclopropyl, substituted-phenyl, or the small volume substituted radicals such as the straight or branched alkyl of 1-10 carbon atom, M is sodium ion, potassium ion, ammonium radical ion, calcium ion or magnesium ion, R11 is hydrogen, or the straight or branched alkyl of 1-10 carbon atom, or organic acid acetic, Z is unitary or the polycarboxy of 1-20 carbon of straight or branched, wherein, R3, R4, R5, R6, R7, R8, R9, R10 is respectively hydrogen, hydroxyl, hydroxyl and carboxylate substituent groups formed by 1-3 carbon atom, the hydrocarbyl ether of 1-3 carbon atom, halogen, or the halohydrocarbon of 1-3 carbon atom, the hydrocarbyl group of 1-10 carbon atom of straight or branched, the naphthenic hydrocarbon of 3-7 carbon atom, substituted aroma ring.
Further, the unitary of 1-20 carbon of described straight or branched or polycarboxy have one or more substituted radical, described substituting group is the simple substituted radical comprising 1-3 carbon atom of halogen atom, hydroxyl or straight or branched.
Further, described substituting group also can be the cycloalkyl of 3-7 carbon atom.
Further, Z is the substituting group aromatic carboxylic containing aromatic ring structure,
Wherein n is the integer of 0-20, and X, Y are respectively the simple substituted radical comprising 1-3 carbon atom of halogen atom, hydroxyl or straight or branched.
Further, described R1, R2, R12 are hydrogen, methyl, ethyl, propyl group, vinyl, methoxyl group or oxyethyl group.
Further, described R11 substituted radical is methyl, ethyl, propyl group, methyl esters or ethyl ester.
Further, described R3, R4, R5, R6, R7, R8, R9, R10 are hydroxyl, hydroxy carboxylic acid ester, acetic ester, the methoxyl group of S steric configuration, oxyethyl group, fluorine, chloromethyl, cyclopropyl, the fluorophenyl of para-orientation or phenyl.
Further, described Z is sulfate ion, phosphate anion, nitrate ion, sulfite ion, orthophosphite ions, nitrite ion, pyrosulfuric acid radical ion or pyrophosphate ion.
Further, in the hydrocarbyl group of 1-10 carbon atom of straight or branched, optionally replaced by one or more substituted radical, described substituting group is selected from the simple substituted radical comprising 1-3 carbon atom of halogen atom, hydroxyl or straight or branched.
Further, in the naphthenic hydrocarbon of 3-7 carbon atom, optionally replaced by one or more substituted radical, described substituting group is selected from: the simple substituted radical comprising 1-3 carbon atom of halogen atom, hydroxyl or straight or branched.
Further, described indole structure substitute by saturated, the unsaturated or aromatic heterocycle of five yuan or hexa-atomic, saturated, the unsaturated or aromatic heterocycle of described five yuan or hexa-atomic comprises one or more heteroatoms being selected from nitrogen, oxygen, sulphur.
Further, described indole structure is poly-substituted quinoline, the ring structure of saturated, the unsaturated or aromatic heterocycle split of a part of structure of described poly-substituted quinoline and five yuan or hexa-atomic.
Further, saturated, the unsaturated or aromatic heterocycle of described five yuan or hexa-atomic is
Further, present invention also offers a preferred compound, its compound name is called S-6-(2 – (3-(4-fluorophenyl)-1-sec.-propyl-1H-indoles-2-base)-vinyl)-5,6-dihydropyrane-2 ketone, and its structural formula is
Further, present invention also offers a preferred compound, its compound name is called S-6-(2 – (3-(4-fluorophenyl)-1-sec.-propyl-1H-indoles-2-base)-ethyl)-5,6-dihydropyrane-2 ketone, and its structural formula is
Further, present invention also offers a preferred compound, its compound name is called 7 – (3-(4-fluorophenyl)-1-sec.-propyl-1H-indoles-2-base)-5-olefin(e) acid sodium in hydroxyl-heptan-2,6-2-, and its structural formula is
Further, present invention also offers a preferred compound, its compound name is called 7 – (3-(4-fluorophenyl)-1-sec.-propyl-1H-indoles-2-base)-5-hydroxyl-hept-2-ene" acid sodium, and its structural formula is
Further, present invention also offers a preferred compound, its compound name is called 7 – (3-(4-fluorophenyl)-1-sec.-propyl-1H-indoles-2-base)-5-enoic acid hemicalcium salt in hydroxyl-heptan-2,6-2-, and its structural formula is
Further, present invention also offers a preferred compound, its compound name is called 7 – (3-(4-fluorophenyl)-1-sec.-propyl-1H-indoles-2-base)-5-hydroxyl-hept-2-ene" acid half calcium salt, and its structural formula is
Further, present invention also offers a preferred compound, its compound name is called 7 – (3-(4-fluorophenyl)-1-sec.-propyl-1H-indoles-2-base)-5-e pioic acid methyl ester in hydroxyl-heptan-2,6-2-, and its structural formula is
Further, present invention also offers a preferred compound, its compound name is called 7 – (3-(4-fluorophenyl)-1-sec.-propyl-1H-indoles-2-base)-5-hydroxyl-hept-2-ene" acid methyl esters, and its structural formula is
Further, present invention also offers a preferred compound, its compound name is called 7 – (3-(4-fluorophenyl)-1-sec.-propyl-1H-indoles-2-base)-5-olefin(e) acid in methanoyl-heptan-2,6-2-, and its structural formula is
Further, present invention also offers a preferred compound, its compound name is called 7 – (3-(4-fluorophenyl)-1-sec.-propyl-1H-indoles-2-base)-5-methanoyl-hept-2-ene" acid, and its structural formula is
Further, present invention also offers a preferred compound, its compound name is called 7 – (3-(4-fluorophenyl)-1-sec.-propyl-1H-indoles-2-base)-5-olefin(e) acid in nicotinoyl-heptan-2,6-2-, and its structural formula is
Further, present invention also offers a preferred compound, its compound name is called 7 – (3-(4-fluorophenyl)-1-sec.-propyl-1H-indoles-2-base)-5-nicotinoyl-hept-2-ene" acid, and its structural formula is
Further, present invention also offers a preferred compound, its compound name is called 7-(3-(4-fluorophenyl)-1-sec.-propyl-1H-indoles-2-base)-5-hydroxyl-heptan-2,6-diolefinic acid-((3S, 3AR, 6S, 6AR)-6 (nitre oxygen base) hexahydro furyl also (3,2b) furans-3 base) ester, its structural formula is
Further, present invention also offers a preferred compound, its compound name is called 7-(3-(4-fluorophenyl)-1-sec.-propyl-1H-indoles-2-base)-5-hydroxyl-hept-2-ene" acid-((3S, 3AR, 6S, 6AR)-6 (nitre oxygen base) hexahydro furyl also (3,2b) furans-3 base) ester, its structural formula is
Further, present invention also offers a kind of medicinal compositions, containing the compound in any one that significant quantity is above-mentioned or pharmacy acceptable salt, ester and pharmaceutically acceptable carrier or mixture.
Further, present invention also offers above-mentioned compound in any one and analogue, its prodrug and active metabolite and aforesaid compound pharmaceutically acceptable salt, ester or above-mentioned medicinal compositions preparation treatment reduce blood lipid level or prevent and treat coronary heart disease, purposes in high blood cholesterol drug that atherosclerosis that hyperlipidemia causes, diabetes cause.
Further, described reduction blood lipid level refers to or any several in five indexs (high-density lipoprotein (HDL), low density albumen, very low-density lipoprotein, triglyceride level, TL) reducing blood fat.
Present invention also offers a kind of compound obtained based on medicine principle of hybridization, comprise the hydroxyl utilizing above-mentioned described compound, hydroxy-acid group is with preventing and treating hyperlipidemia, hypertension, the relative disease drug mains such as hyperglycemia want the corresponding hydroxyl of component cpd, carboxylic acid, the soda acid salify of the groups such as amido, become ester, become acid amides, become the splicing objects such as ether.
The present invention has carried a kind of new HMGR inhibitor (statins be namely commonly called as), be not only the toxic side effects will eliminated or at least weaken this kind of medicine and bring, and pharmacologically active value is improved.Pharmacology test result shows, after such the polysubstituted indoles statin derivative described in invention and lactone open loop thereof, carboxylic acid and ester thereof are relative to not derivative statin HMGR enzyme inhibition activity IC on the whole
50test value tool is significantly improved.
The present invention is polysubstituted indoles statin derivative or its active metabolite of 2-alkene-3-hydroxypentanoic acid and salt thereof or the ester formed after a kind of structure shown in formula I contains 2-hexenolactone fragment and lactone open loop thereof:
This compounds or its active metabolite are 3-hydroxy-3-methyl penta 2 phthalein CoA-reductase (3-Hydroxy-3-methylglutaryl-CoA Reductase, HMGR) the 3-hydroxyl of its six-membered cyclic lactone form of 3,5-dihydroxy-acids of inhibitor be replaced by fluorine atoms after derivative.Its structural formula such as formula I, wherein:
Part A is the 2-alkene-3-hydroxypentanoic acid and salt thereof or ester that are formed after 2-hexenolactone fragment or its lactone open loop;
Shown in I, when its structure is 2-hexenolactone fragment, its substituent group R 1, R2, R12 are the small volume substituted radicals such as the straight or branched alkyl of the straight chain of the 1-10 such as hydrogen, methyl, ethyl, propyl group, a vinyl carbon atom saturated or unsaturated alkyl or cyclopropyl, substituted-phenyl and the 1-10 such as methoxyl group, an oxyethyl group carbon atom, R1 and R2, R12 are preferably hydrogen or methyl.
When its structure is the carboxylicesters of open loop form, its substituent group R 1, R2, R12 are the saturated or unsaturated alkyl of the straight chains such as hydrogen, methyl, ethyl, propyl group, vinyl or cyclopropyl, substituted-phenyl and methoxyl group, oxyethyl group etc. small volume substituted radical, and R10 is preferably hydrogen.Become the R10 substituted radical of ester can be straight or branched alkyl or other organic acid acetic of 1-10 the carbon atoms such as methyl, ethyl, propyl group with carboxylic acid, be preferably methyl esters or ethyl ester same, hydroxy-acid group also can with basic metal or alkaline-earth metal M salify, M metal-salt comprises the sodium salt of monovalence, sylvite or ammonium salt, the calcium salt of divalence, magnesium salts, particular certain cancers and calcium salt.
Can form organic or inorganic acid ester with radicals X addition for the alcoholic extract hydroxyl group exposed after lactone open loop, its implication is as follows:
A) organic acid acetic
The unitary of 1-20 carbon of-straight or branched or multi-carboxylate, a preferred 1-10 carbon, is optionally replaced by one or more substituted radical, and described substituting group is selected from: the simple substituted radical comprising 1-3 carbon atom of halogen atom, hydroxyl or straight or branched
Described substituting group also can be the cycloalkyl of 3-7 carbon atom, a preferred 3-5 carbon atom.
-substituting group aromatic carboxylic acid containing aromatic ring structure is as substituted aroma carboxylic acid:
Wherein n is the integer of 0-20, preferred 1-3;
X, Y represent substituting group, are selected from: the simple substituted radical comprising 1-3 carbon atom of halogen atom, hydroxyl or straight or branched
B) inorganic acid ester
Inorganic acid ester comprises various oxygen-containing inorganic acid ester, can be sulfuric acid, phosphoric acid, nitric acid, sulfurous acid, phosphorous acid, nitrous acid or pyrosulfuric acid, tetra-sodium etc., preferably sulfuric acid phosphoric acid and nitric acid.
C part be poly-substituted quinoline or other condensed ring of the rigid plane poly-substituted quinoline of lipophilic or group replacement, and structure is as shown in the formula showing
In formula, specific definition is as follows:
A) female ring structure
-poly-substituted quinoline or other coplanar split heterocycles, be selected from indoles, poly-substituted quinoline etc.
Saturated, the unsaturated or aromatic heterocycle of-following five yuan or hexa-atomic, comprise one or more heteroatoms being selected from nitrogen, oxygen, sulphur, such as, and poly-substituted quinoline part structure is with the ring structure of saturated, the unsaturated or aromatic heterocycle split of above-mentioned five yuan or hexa-atomic, is selected from:
Preferred following female ring structure:
B) substituting group in female ring structure
R3, R4, R5, R6, R7, R8, R9, R10, R11 are defined as following substituted radical:
-unsubstituted, directly connects a hydrogen atom
-hydroxyl, or hydroxyl and containing carboxylicesters formed by 1-3 carbon atom, preferably hydroxyl or hydroxy carboxylic acid ester, acetic ester
The hydrocarbyl ether of-1-3 carbon atom, is preferably methoxyl group, the oxyethyl group of S steric configuration.
-halogen, or the halohydrocarbon of 1-3 carbon atom, be preferably fluorine or chlorine methyl.
The hydrocarbyl group of 1-10 carbon atom of-straight or branched, is optionally replaced by one or more substituted radical, and described substituting group is selected from: the simple substituted radical comprising 1-3 carbon atom of halogen atom, hydroxyl or straight or branched, is preferably sec.-propyl.
The naphthenic hydrocarbon of-3-7 carbon atom, optionally replaced by one or more substituted radical, described substituting group is selected from: the simple substituted radical comprising 1-3 carbon atom of halogen atom, hydroxyl or straight or branched, preferred cyclopropyl.
-substituted aroma ring, substituted radical comprises the alkyl of halogen, a 1-3 carbon atom.Be preferably fluorophenyl or the phenyl of para-orientation.
Part B is the syndeton of A and C part
-be the carbochain of two carbon atoms, can be vinyl or ethyl, be preferably ethyl.
The present invention is the Drug combination that will provide type I compound and at least one Cardiovarscular on the other hand, and described medicine is selected from the medicines such as ACE inhibitor, Angiotensin Ⅱ receptor antagonist, beta adrenergic blocker, calcium ion channel blocker, antithrombotic agent.
The medicines such as suitable ACE inhibitor, Angiotensin Ⅱ receptor antagonist, beta adrenergic blocker, calcium ion channel blocker, antithrombotic agent can find it to describe in detail in such as clinical medicine handbook.
This kind of compou nd synthesis method of the present invention is simple, existing procucts bulk drug particularly can be utilized for raw material, simply react can obtain through a few step.Relative to the statin analogue (referring to HMGR enzyme inhibitors) of business development, its inhibitory enzyme activity IC
50value is compared or the same order of magnitude or have the lower order of magnitude, and which show this compounds of the present invention can as the medicinal application reducing blood fat.
Compound of the present invention is 3-hydroxy-3-methyl penta 2 phthalein CoA-reductase (3-Hydroxy-3-methylglutaryl-CoA Reductase, HMGR) inhibitor.
The present invention includes steric isomer and optically active isomer, such as corresponding isomer or diastereomer, its Producing reason is the asymmetry possessed in structure in this compounds selected.The same with most drug, it also can have crystal formation, and the different crystal forms that in this compounds, each single chemical substance has also all is included in class of the present invention.
This compounds of the present invention also can be the form of solvation, especially methyl alcohol, ethanol, the small molecule solvent of the larger polarity such as water.Its solvation can occur in the production process of the composition of this compound or inclusion compound, or the water absorbability had due to compound, solvation can occur through certain hour.
Compound of the present invention and active metabolite thereof are the derivatives being called as prodrug or metabolic activity thing.
2-alkene-3-the hydroxypentanoic acid formed after compound lactone open loop of the present invention has hydroxyl and hydroxy-acid group, can react change into corresponding salt with corresponding organic bases and mineral alkali in organic solvent (ethanol, acetone, methylene dichloride, tetrahydrofuran (THF) etc.).The salt that mineral alkali becomes comprises sodium salt, calcium salt, sylvite, ammonium salt etc.Particular certain cancers and calcium salt.
There is after the open loop of the compounds of this invention lactone 2-alkene-3-hydroxypentanoic acid, containing hydroxy-acid group and alcoholic OH groups, can add with suitable oxygen acid and alcohol compound and be shaped as ester.
After the open loop of the compounds of this invention lactone, hydroxyl can obtain carboxylicesters with oxygen acid addition, and these esters comprise the ester (these acid are reacted into ester with the alcoholic extract hydroxyl group exposed after lactone hydrolysis) obtained with organic or inorganic oxygen acid institute addition.These oxygen-containing inorganic acids include but not limited to (Asia) sulfuric acid, (Asia) phosphoric acid, nitric acid, carbonic acid, (former) silicic acid, and corresponding (Asia) hydrogen sulfuric acid ester, (Asia) hydrogen phosphate etc.Organic acid comprises simple alkyl acid as formic acid, acetic acid, propionic acid, hexanodioic acid, alginic acid, the amino acid such as aspartic acid, phenylformic acid, Phenylsulfonic acid, butyric acid, citric acid, dextrocamphoric acid, camphorsulfonic acid, cyclopentyl propionic acid, glucosulfone acid, dodecyl sulphate, ethyl sulfonic acid, fumaric acid, glucoheptonic acid, Phosphoric acid glycerol esters, enanthic acid, caproic acid, 2-ethylenehydrinsulfonic acid, lactic acid, toxilic acid, methylsulfonic acid, 2-naphthene sulfonic acid, oxalate, flutter acid, pectinic acid, 3-phenylpropionic acid, picric acid, PIVALIC ACID CRUDE (25), succsinic acid, tartrate, toluenesulphonic acids, palmitinic acid can be used for the parmacodynamics-less activities such as undeeanoic acid the organic carboxyl acid that same hydroxyl becomes ester.
After the open loop of the compounds of this invention lactone, carboxylic acid can add with suitable alcohol and is shaped as carboxylicesters.Organic Alcohol comprises simple alkyl alcohol as methyl alcohol, ethanol, propyl alcohol, hexylene glycol, the parmacodynamics-less activities such as glycerol can be used for the alcohols that same carboxylic acid becomes ester.
Indication of the present invention is that compound and active metabolite thereof include but not limited to the compound in claims to carry out split with existing known related drugs, these splits comprise and covalently boundly include but not limited to into ester, become acid amides to become complicated salt or the part A in formula I are carried out the splicing of fragment with other related drugs.All part A in structural formula carried out split with other medicine and has and suppress the compound of HMGR enzymic activity to be all analogue and the active metabolite thereof of indication in patent claims of the present invention 1.
Related drugs in above-mentioned includes but not limited to the various kinds of drug for preventing and treating three height (hyperlipidemia, hypertension, hyperglycemia).For patient clinically, one of three senior middle schools is not go out item separately, be usually that two or three appear at the different steps of patient disease simultaneously, thus drug combination is necessary, and this contributes to the toxic side effect reducing dose and alleviate medication treatment.
Above-mentioned middle related drugs includes but not limited to phenoxy acetic acid class, the nicotinic acid class for the treatment of hyperlipidemia.
Above-mentioned middle related drugs includes but not limited to treat hypertensive Mg-ATP enzyme inhibitors class (as serpentine), α
2receptor stimulant (as clonidine, methyldopa), beta-blockers (atenolol USP 23 as in Luo Er class), angiotensin-convertion enzyme inhibitor (benazepril as in pril), angiotensinⅡantagonist (telmisartan of class as smooth in sand), nitric oxide donors medicine (isosorbide mononitrate as nitrate esters) etc., these medicines all contain amido or alcoholic extract hydroxyl group, hydroxy-acid group, can become acid amides with compound of the present invention by being dehydrated into ester, soda acid salify obtains the medicine splicing object of being correlated with.
The present invention includes steric isomer and optically active isomer, such as corresponding isomer or diastereomer, its Producing reason is the asymmetry possessed in structure in this compounds selected.The same with most drug, it also can have crystal formation, and the different crystal forms that in this compounds, each single chemical substance has also all is included in class of the present invention.
Compound of the present invention can use suitable material to prepare as raw material according to the general approach of the following stated, and carrys out concrete example explanation by embodiment below.Certainly, the condition of the citing compound producing step in embodiment and the various known rational change of method also can for the preparation of these compounds.Except as otherwise noted, organic solvent used in embodiment and reagent (methylene dichloride, ethyl acetate, sherwood oil and triethylamine etc.) be commercial reagent and do except water treatment or the molecular sieve after using activation do Non-aqueous processing in a small amount through the ordinary method that this area is approved.Described analytical and testing instrument and condition unless otherwise stated: HRMS high resolution mass spectrum is Brooker,Switzerland company solanX-70FT-MS, and H-NMR nucleus magnetic hydrogen spectrum volance III 500M, test solvent is CDCl
3.Spectral data is attached.
Prepare the generalized flowsheet of the compounds of this invention:
To include but not limited to that the carboxylic metallic salt (mainly calcium salt, sodium salt) of commercially available Statins bulk drug is for raw material, dissociates through certain density hcl acidifying, and obtain crude carboxylic acid through suitable organic solvent extraction final vacuum is concentrated.This crude product, without refining, namely carries out lactonizing of next step.
The DMAP of above-mentioned crude carboxylic acid and catalytic amount, the magnetic stir bar of suitable size joins in suitable reaction vessel, after organic solvent dissolution in the lump.Drip a certain amount of dicyclohexylcarbodiimide solution, stirred at ambient temperature reaction is spent the night.After thin-layer chromatography monitoring reacts completely, suction filtration, filtrate anhydrous sodium sulfate drying, concentrated, column chromatography for separation (PE/EA gradient elution) obtains lactone.
A certain amount of organic solvent and tosic acid and a certain amount of lactone join in reaction vessel, and return stirring reacts.After for some time, after thin-layer chromatography monitoring reacts completely, add the NaHCO of 5%
3aqueous solution jolting, separatory takes off a layer organic phase, anhydrous sodium sulfate drying, concentrated, and column chromatography for separation (PE/EA gradient elution) obtains of the present invention containing 2-hexenolactone fragment statin derivative.
By the above-mentioned lactone form containing 2-hexenolactone fragment statin derivative, open loop 2-alkene-5-hydroxypentanoic acid form can be obtained under suitable alkaline solution and organic solvent, thus expose Carboxylic acid and alcohol oh group, further with the affixture such as acid, alkali addition salify, ester, acid amides.
Embodiment
The following example illustrates and unrestricted method and composition of the present invention.Other suitable amendments of different condition and product and adjustment are normal and approved.To those skilled in the art, obviously also within the scope of the invention.
The preparation of embodiment 1 fluvastatin lactone and the reduction of fluvastatin lactone
Take the fluvastatin sodium salt of 5.00g, join in the eggplant-shape bottle of 250ml, add the dilute hydrochloric acid of 20 times of concentrated hydrochloric acid dilutions of the methylene dichloride of 100ml and about 10ml, violent jolting, stratification.Get upper strata aqueous phase, pH detection paper controls when 2-3, can think completely free.Separatory, 100ml methylene dichloride equivalent extracts three times, merges lower floor organic phase, the backwash of 20ml water once, organic phase anhydrous sodium sulfate drying.45 DEG C of vacuum are spin-dried for, and oil pump is evacuated to and occurs white foaming material, and cooling, smashs to obtain white powder 4.23g to pieces, and this fluvastatin crude carboxylic acid is not refining namely for next step.
Take the above-mentioned fluvastatin crude carboxylic acid of 4.00g, join in the there-necked flask of 250ml, add the powdered molecular sieves of 5g, the p dimethylamino pyridine of 0.05g and the stirrer of suitable size, displaced air also with nitrogen protection, adds the methylene dichloride of 100ml.Inserted in ice bath by reaction vessel and stir, the dicyclohexylcarbodiimide slowly injecting 5.0g is dissolved in 20ml dichloromethane solution.Within about 10 minutes, dropwise, reaction unit is shifted out to react under room temperature and spend the night.After thin-layer chromatography monitoring reacts completely, suction filtration, after filtrate anhydrous sodium sulfate drying, vacuum is spin-dried for, and rapid column chromatography is separated (PE/EA gradient elution) and obtains fluvastatin lactone 2.18g.MP 65.7-66.8 DEG C, HRMS (ESI): C
24h
24fNO
3, 394.18549 (M+H)
+theoretical value is 394.18185, H-NMR:7.53 (dd, J=13.0, 8.2Hz, 2H), 7.42 – 7.35 (m, 2H), 7.21 (t, J=7.3Hz, 1H), 7.15 – 7.06 (m, 3H), 6.76 (d, J=16.1Hz, 1H), 5.68 (dd, J=16.0, 6.0Hz, 1H), 5.30 – 5.23 (m, 1H), 4.83 (dt, J=13.7, 6.7Hz, 1H), 4.36 (s, 1H), 2.76 (dd, J=17.8, 4.8Hz, 1H), 2.70 – 2.61 (m, 1H), 2.00 – 1.89 (m, 1H), 1.68 – 1.64 (m, 6H)
Above-mentioned fluvastatin lactone is taken 500mg, joins in 25ml reaction tubes, add the Pt/c catalytic hydrogenation catalyst of the tetrahydrofuran (THF) of stirrer and about 5ml methyl alcohol and about 1ml and 10% of 20mg, displaced air, room temperature normal pressure catalytic hydrogenation.After 12 hours, thin-layer chromatography monitoring reacts completely.Filter filtering Pt/C, filtrate is after anhydrous sodium sulfate drying, and vacuum is spin-dried for, and column chromatography for separation (PE/EA gradient elution) obtains fluvastatin lactone reduzate 355mg, and HRMS (ESI): C
24h
26fNO
3, 396.20059 (M+H)
+, theoretical value is 396.19750; H-NMR:7.55 (dd, J=23.9,8.0Hz, 2H), 7.42 – 7.34 (m, 2H), 7.15 (dd, J=18.0,8.8Hz, 3H), 7.08 (t, J=7.3Hz, 1H), 4.70 – 4.60 (m, 1H), 3.94 (s, 1H), 2.79 (t, J=7.4Hz, 2H), 2.54 – 2.35 (m, 2H), 1.69 (t, J=11.7Hz, 6H), 1.56 – 1.32 (m, 3H)
The preparation of embodiment 2 compound 001,002
The magnetic stir bar of suitable size joins in two mouthfuls of reaction flasks of 50ml; the fluvastatin lactone displaced air of the tosic acid (PBSA) and 1.50g that add 0.50g is also with nitrogen protection; by reaction vessel reflux after the tetrahydrofuran (THF) of injection 30ml; after thin-layer chromatography monitoring reacts completely; after thin-layer chromatography monitoring reacts completely, add the NaHCO of 5%
3aqueous solution jolting, separatory takes off a layer organic phase, anhydrous sodium sulfate drying, concentrated, and column chromatography for separation (PE/EA gradient elution) obtains fluvastatin derivative (001) 0.76g containing 2-hexenolactone fragment of the present invention.Same method can obtain 002.
The preparation of embodiment 3 compound 003,004,005,006
Get fluvastatin derivative (001) 1.00g, ice bath after dissolving with tetrahydrofuran (THF) 6ml, after the LiOH solution 1.5ml adding 1mol/L stirs 2 hours, when hcl acidifying with 10% is 2-3 to pH, 45 DEG C of steamings of reducing pressure desolventize, add acetone be about 10ml dissolve after, slowly while stirring drip 10% Na
2cO
3the aqueous solution, has floss and muddy appearance as seen, drops to till no longer there is floss.Be heated to muddy thing dissolve, leave standstill, slow cooling spends the night.Next day obtains needle crystal 0.68g, i.e. fluvastatin derivative sodium salt (003).Same method can obtain reductive derivative sodium salt 004.
Get fluvastatin derivative (001) 1.00g, ice bath after dissolving with tetrahydrofuran (THF) 6ml, after the LiOH solution 1.5ml adding 1mol/L stirs 2 hours, when hcl acidifying with 10% is 7-8 to pH, 45 DEG C of steamings of reducing pressure desolventize, add ethanol be about 10ml dissolve after, slowly while stirring drip 10% CaCl
2the aqueous solution, stirring is spent the night, and separate out solid, suction filtration, obtains half calcium salt crude product.With the methanol/water mixing solutions of 50% volume ratio, refined fluvastatin derivative half calcium salt (005) 0.75g of recrystallization.Same method can obtain fluvastatin reductive derivative half calcium salt 006.
The preparation of embodiment 4 compound 007,008
Get fluvastatin derivative (001) 1.00g, ice bath after dissolving with tetrahydrofuran (THF) 6ml, after the LiOH solution 2.5ml adding 1mol/L stirs 2 hours, by this water oil mixt washed with diethylether three times (5 × 3), after washing, discard upper organic phase at every turn.Aqueous phase with 10% hcl acidifying be 2-3 to pH time, add water and ethyl acetate separatory extracts three times (6 × 3), organic phase anhydrous sodium sulfate drying, 45 DEG C of steamings of reducing pressure desolventize and obtain fluvastatin derivative lactone open loop crude carboxylic acid 0.89g.
Above-mentioned crude carboxylic acid is dissolved in the anhydrous methanol of 25ml, after adding the p dimethylamino pyridine of catalytic amount, adds 1.2gDCC (dicyclohexylcarbodiimide) and be dissolved in 5ml methyl alcohol gained solution under ice bath.Remove ice bath, stirring reaction spends the night, and after thin-layer chromatography monitoring reacts completely, suction filtration, concentrating under reduced pressure, silica gel column chromatography separating purification obtains fluvastatin derivative carboxylate methyl ester (007) 0.75g.Same method can obtain compound 008.
The preparation of embodiment 5 compound 009,010
The lactone of fluvastatin derivative described in Example 5 open loop crude carboxylic acid 0.65g is dissolved in the mixed solvent of the 1:1 of formic acid and methylene dichloride, after adding the p dimethylamino pyridine of catalytic amount, under ice bath, add the mixed solvent gained solution that 1.2gDCC (dicyclohexylcarbodiimide) is dissolved in the 1:1 of 5ml formic acid and methylene dichloride.Remove ice bath, stirring reaction spends the night, and after thin-layer chromatography monitoring reacts completely, suction filtration, concentrating under reduced pressure, silica gel column chromatography separating purification obtains fluvastatin derivative carboxylic acid manthanoate (009) 0.57g.Same method can obtain compound 010.
The preparation of embodiment 6 compound 011,012
The lactone open loop crude carboxylic acid 0.65g of fluvastatin derivative described in Example 5 and 2g nicotinic acid are dissolved in the methylene dichloride of 15ml, after adding the p dimethylamino pyridine of catalytic amount, add 1.2gDCC (dicyclohexylcarbodiimide) under ice bath and be dissolved in 5ml methylene dichloride gained solution.Remove ice bath, stirring reaction spends the night, and back flow reaction is after about 1 hour, and react completely through thin-layer chromatography monitoring, suction filtration, filtrate reduced in volume, silica gel column chromatography separating purification obtains fluvastatin derivative nicotinate (011) 0.57g.Same method can obtain compound 012.
The preparation of embodiment 10 compound 013,014
The lactone open loop crude carboxylic acid 0.65g of fluvastatin derivative described in Example 5 and 2.5g isosorbide mononitrate are dissolved in the acetonitrile of 50ml, after adding the p dimethylamino pyridine of catalytic amount, add 1.2gDCC (dicyclohexylcarbodiimide) under ice bath and be dissolved in 5ml acetonitrile gained solution.Dropwise recession except ice bath, heating in water bath back flow reaction is spent the night, and react completely through thin-layer chromatography monitoring, suction filtration, filtrate reduced in volume, silica gel column chromatography separating purification obtains fluvastatin derivative isosorbide mononitrate (013) 0.26g.Same method can obtain compound 014.
Embodiment 11 compound activity is tested
Following description of test the compounds of this invention is to the restraining effect experimental principle of the enzymic activity of HMG-CoA reductase (HMGR)
3-hydroxy-3-methyl glutaryl coenzyme (HMG-CoA) reductase enzyme is the key enzyme of this pathways metabolism of catalysis acetyl-CoA synthesis mevalonic acid in body, and it reacts below catalysis under physiological environment:
HMG-CoA+NADPH+2H
+→mevalonic acid+2NADP
++CoASH
Because NADPH has absorption peak at 340nm place, therefore the activity of HMG-CoA reductase can have been come by the reduction yield of division of labor photometry 340nm place's photoabsorption.
Material and instrument: (this test kit comprises HMG-CoA Reductase Assay Kit: HMGR, HMG-CoA, NADP-H, damping fluid, pitavastatin solution), other subsidiary material are 96 orifice plates, ultrapure water, accurate pipettor (each one of 2-20ul and 0.5-2ul) and supporting disposable rifle head, spectrophotometer or microplate reader
Medicament preparation and preparation
5 of 10ml times of concentration buffer liquid are diluted to 1 times of damping fluid (namely 5 times of liquid of 10ml add the ultrapure water of 40ml), when with 96 orifice plate, 1 times of liquid of 1ml can carry out the test of 5 samples, is stored in ice stand-by, and remaining 5 times of damping fluids are in-20 DEG C of preservations.The NADPH of 25mg needs 1 times of damping fluid of supplementary 1.5ml, mixes-20 DEG C of preservations.
Method and flow process
Thaw: thaw enzyme require more on ice or keep surrounding environment cooling, try not enzyme to be placed on ice more than 60 minutes, because long meeting storage period causes the activity of enzyme to reduce.Other thaw and can at room temperature carry out, and should be kept on ice once thaw.
Instrument adjustment: before experiment starts, temperature is adjusted to 37 DEG C, absorbing wavelength is 340nm, gets out dynamic routine.96 orifice plate samples read a number in every 20 seconds, amount to 10 minutes.
The form provided according to kit and flow process add the reaction solution of suitable volumes
Form
Reagent Standard entertion mode
Flow process
A, adds 1 times of quantitative damping fluid in each hole;
B, add testing sample in the hole except blank and positive control
C, add supplemented damping fluid NADPH in each hole
D, adds substrate HMG-CoA in each hole
E, enzyme-added HMGR is in the hole except blank
F, mixes reaction solution, especially with during 96 orifice plate test sample at least will before survey first time absorbancy strong stirring 10 seconds
G, opens dynamic routine, observes the change of absorbancy
Carry out active testing according to the method that kit introduces, obtain absorbancy downcurve, the slope of decline indicates the inhibition of different sample to HMGR enzyme, carries out mathematics manipulation and matching to the slope curve of gained,
According to the explanation of test kit, use formulae discovery activity data below
Wherein: parameter 12.44 represents 12.44mM/cm, because the rejection ratio of NADPH under 340nm is 6.22mM/cm, the NADPH of twice in reaction mechanism, therefore be 12.44
TV is the cumulative volume of reaction solution, and 96 orifice plates are 0.2ml
V represents the volume of reductase enzyme, the volume of enzyme namely used in each test
0.6 represents the concentration under use mg-Protein unit (mgP)/ml, and be generally 0.50-0.70, the concentration that test kit provides here is 0.6
LP represents optical path width, and 96 orifice plates are 0.55cm
The NADPH that Unit is defined as per minute 1umol at 37 DEG C is converted into NADP+, and concrete unit is umol/min/mg protein
A340 represents the absorbancy of sample at 340 nano wave lengths, and Δ A340 represents corresponding absorbancy changing value
Mins
samplerepresent sample test time used, unit be minute, the Mins of correspondence
blankrepresent that blank sample tests the time used, the same Mins of its numerical value
sampleequal.
overall expression experienced by Mins
samplethe velocity of variation of sample absorbancy under wavelength 340 nanometer in time, unit is min
-1, same
represent the velocity of variation of blank sample.
Then under certain concentration, the inhibiting rate of certain sample is:
Wherein activity data
activityrepresent the Activity activity value tested and calculated according to formula correspondence, activity data
sempierepresent the activity value after adding inhibitor sample.
Measure the inhibiting rate data of same sample under different concns, the half-inhibition concentration IC of this compound to 3-hydroxy-3-methyl glutaryl coenzyme (HMG-CoA) reductase enzyme can be drawn
50.
Claims (31)
1. a compound, its structural formula is as follows,
, or
, or
, wherein, R1, R2, R12 is hydrogen, saturated or the unsaturated alkyl of the straight chain of 1-10 carbon atom or cyclopropyl, substituted-phenyl, or the small volume substituted radicals such as the straight or branched alkyl of 1-10 carbon atom, M is sodium ion, potassium ion, ammonium radical ion, calcium ion or magnesium ion, R11 is hydrogen, or the straight or branched alkyl of 1-10 carbon atom, or organic acid acetic, Z is unitary or the polycarboxy of 1-20 carbon of straight or branched, R3, R4, R5, R6, R7, R8, R9, R10 is respectively hydrogen, hydroxyl, hydroxyl and carboxylate substituent groups formed by 1-3 carbon atom, the hydrocarbyl ether of 1-3 carbon atom, halogen, or the halohydrocarbon of 1-3 carbon atom, the hydrocarbyl group of 1-10 carbon atom of straight or branched, the naphthenic hydrocarbon of 3-7 carbon atom, substituted aroma ring.
2. a kind of compound according to claim 1, it is characterized in that: the unitary of 1-20 carbon of described straight or branched or polycarboxy have one or more substituted radical, described substituting group is the simple substituted radical comprising 1-3 carbon atom of halogen atom, hydroxyl or straight or branched.
3. a kind of compound according to claim 2, is characterized in that: described substituting group is the cycloalkyl of 3-7 carbon atom.
4. a kind of compound according to claim 1, is characterized in that: Z is the substituting group aromatic carboxylic containing aromatic ring structure,
Wherein n is the integer of 0-20, and X, Y are respectively the simple substituted radical comprising 1-3 carbon atom of halogen atom, hydroxyl or straight or branched.
5. a kind of compound according to claim 1, is characterized in that: described R1, R2, R12 are hydrogen, methyl, ethyl, propyl group, vinyl, methoxyl group or oxyethyl group.
6. a kind of compound according to claim 1, is characterized in that: described R11 substituted radical is methyl, ethyl, propyl group, methyl esters or ethyl ester.
7. a kind of compound according to claim 1, is characterized in that: described R3, R4, R5, R6, R7, R8, R9, R10 are hydroxyl, hydroxy carboxylic acid ester, acetic ester, the methoxyl group of S steric configuration, oxyethyl group, fluorine, chloromethyl, cyclopropyl, the fluorophenyl of para-orientation or phenyl.
8. a kind of compound according to claim 1, is characterized in that: described Z is sulfate ion, phosphate anion, nitrate ion, sulfite ion, orthophosphite ions, nitrite ion, pyrosulfuric acid radical ion or pyrophosphate ion.
9. a kind of compound according to claim 1, it is characterized in that: in the hydrocarbyl group of 1-10 carbon atom of straight or branched, optionally replaced by one or more substituted radical, described substituting group is selected from the simple substituted radical comprising 1-3 carbon atom of halogen atom, hydroxyl or straight or branched.
10. a kind of compound according to claim 1, it is characterized in that: in the naphthenic hydrocarbon of 3-7 carbon atom, optionally replaced by one or more substituted radical, described substituting group is selected from: the simple substituted radical comprising 1-3 carbon atom of halogen atom, hydroxyl or straight or branched.
11. a kind of compounds according to claim 1, it is characterized in that: described indole structure substitute by saturated, the unsaturated or aromatic heterocycle of five yuan or hexa-atomic, saturated, the unsaturated or aromatic heterocycle of described five yuan or hexa-atomic comprises one or more heteroatoms being selected from nitrogen, oxygen, sulphur.
12. a kind of compounds according to claim 1, is characterized in that: described indole structure is poly-substituted quinoline, the ring structure of saturated, the unsaturated or aromatic heterocycle split of a part of structure of described poly-substituted quinoline and five yuan or hexa-atomic.
13. a kind of compounds according to claim 11 or 12, is characterized in that: saturated, the unsaturated or aromatic heterocycle of described five yuan or hexa-atomic is
,
,
,
,
,
,
,
,
,
,
,
,
,
, or
.
14. a kind of compounds according to claim 1, it is characterized in that: its compound name is called S-6-(2 – (3-(4-fluorophenyl)-1-sec.-propyl-1H-indoles-2-base)-vinyl)-5,6-dihydropyrane-2 ketone, its structural formula is
。
15. a kind of compounds according to claim 1, it is characterized in that: its compound name is called S-6-(2 – (3-(4-fluorophenyl)-1-sec.-propyl-1H-indoles-2-base)-ethyl)-5,6-dihydropyrane-2 ketone, its structural formula is
。
16. a kind of compound according to claim 1, is characterized in that: its compound name is called 7 – (3-(4-fluorophenyl)-1-sec.-propyl-1H-indoles-2-base)-5-olefin(e) acid sodium in hydroxyl-heptan-2,6-2-, and its structural formula is
。
17. a kind of compounds according to claim 1, is characterized in that: its compound name is called 7 – (3-(4-fluorophenyl)-1-sec.-propyl-1H-indoles-2-base)-5-hydroxyl-hept-2-ene" acid sodium, and its structural formula is
.
18. a kind of compounds according to claim 1, is characterized in that: its compound name is called 7 – (3-(4-fluorophenyl)-1-sec.-propyl-1H-indoles-2-base)-5-enoic acid hemicalcium salt in hydroxyl-heptan-2,6-2-, and its structural formula is
。
19. a kind of compounds according to claim 1, is characterized in that: its compound name is called 7 – (3-(4-fluorophenyl)-1-sec.-propyl-1H-indoles-2-base)-5-hydroxyl-hept-2-ene" acid half calcium salt, and its structural formula is
。
20. a kind of compounds according to claim 1, is characterized in that: its compound name is called 7 – (3-(4-fluorophenyl)-1-sec.-propyl-1H-indoles-2-base)-5-e pioic acid methyl ester in hydroxyl-heptan-2,6-2-, and its structural formula is
。
21. a kind of compounds according to claim 1, is characterized in that: its compound name is called 7 – (3-(4-fluorophenyl)-1-sec.-propyl-1H-indoles-2-base)-5-hydroxyl-hept-2-ene" acid methyl esters, and its structural formula is
。
22. a kind of compounds according to claim 1, is characterized in that: its compound name is called 7 – (3-(4-fluorophenyl)-1-sec.-propyl-1H-indoles-2-base)-5-olefin(e) acid in methanoyl-heptan-2,6-2-, and its structural formula is
。
23.
a kind of compound according to claim 1, is characterized in that: its compound name is called 7 – (3-(4-fluorophenyl)-1-sec.-propyl-1H-indoles-2-base)-5-methanoyl-hept-2-ene" acid, and its structural formula is
。
24. a kind of compounds according to claim 1, is characterized in that: its compound name is called 7 – (3-(4-fluorophenyl)-1-sec.-propyl-1H-indoles-2-base)-5-olefin(e) acid in nicotinoyl-heptan-2,6-2-, and its structural formula is
。
25. a kind of compounds according to claim 1, is characterized in that: its compound name is called 7 – (3-(4-fluorophenyl)-1-sec.-propyl-1H-indoles-2-base)-5-nicotinoyl-hept-2-ene" acid, and its structural formula is
。
26. a kind of compounds according to claim 1, it is characterized in that: its compound name is called 7-(3-(4-fluorophenyl)-1-sec.-propyl-1H-indoles-2-base)-5-hydroxyl-heptan-2,6-diolefinic acid-((3S, 3AR, 6S, 6AR)-6(nitre oxygen base) hexahydro furyl also (3,2b) furans-3 base) ester, its structural formula is
。
27. a kind of compounds according to claim 1, it is characterized in that: its compound name is called 7-(3-(4-fluorophenyl)-1-sec.-propyl-1H-indoles-2-base)-5-hydroxyl-hept-2-ene" acid-((3S, 3AR, 6S, 6AR)-6(nitre oxygen base) hexahydro furyl also (3,2b) furans-3 base) ester, its structural formula is
.
28. 1 kinds of medicinal compositionss, is characterized in that: containing the compound in significant quantity claims 1,14-27 in any one or pharmacy acceptable salt, ester and pharmaceutically acceptable carrier or mixture.
Compound in 29. claims 1,14-27 in any one and analogue, its prodrug and active metabolite and aforesaid compound pharmaceutically acceptable salt, ester or medicinal compositions according to claim 28 preparation treatment reduce blood lipid level or prevent and treat coronary heart disease, purposes in high blood cholesterol drug that atherosclerosis that hyperlipidemia causes, diabetes cause.
30. purposes as claimed in claim 29, is characterized in that: described reduction blood lipid level refers to the high-density lipoprotein (HDL) reducing blood fat, low density albumen, very low-density lipoprotein, triglyceride level, one in TL or any several.
31. 1 kinds of compounds obtained based on medicine principle of hybridization, it is characterized in that: the hydroxyl comprising the compound utilized described in right 1,14-27, hydroxy-acid group is with preventing and treating hyperlipidemia, hypertension, the relative disease drug mains such as hyperglycemia want the corresponding hydroxyl of component cpd, carboxylic acid, the soda acid salify of the groups such as amido, become ester, become acid amides, become the splicing objects such as ether.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410553930.XA CN104327057B (en) | 2014-10-17 | 2014-10-17 | Poly-substituted indole statin lactone dehydrated compound and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410553930.XA CN104327057B (en) | 2014-10-17 | 2014-10-17 | Poly-substituted indole statin lactone dehydrated compound and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104327057A true CN104327057A (en) | 2015-02-04 |
| CN104327057B CN104327057B (en) | 2017-01-18 |
Family
ID=52401877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410553930.XA Expired - Fee Related CN104327057B (en) | 2014-10-17 | 2014-10-17 | Poly-substituted indole statin lactone dehydrated compound and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104327057B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105017231A (en) * | 2015-06-26 | 2015-11-04 | 上海应用技术学院 | Polysubstituted indole statin fluorine-containing modifier and use thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1794987A (en) * | 2003-05-27 | 2006-06-28 | 尼科克斯公司 | Nitrooxyderivatives of fluvastatin, pravastatin, cerivastatin, atorvastatin and rosuvastatin as cholesterol-reducing agents with improved anti-inflammatory, antithrombotic and antiplatelet activity |
-
2014
- 2014-10-17 CN CN201410553930.XA patent/CN104327057B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1794987A (en) * | 2003-05-27 | 2006-06-28 | 尼科克斯公司 | Nitrooxyderivatives of fluvastatin, pravastatin, cerivastatin, atorvastatin and rosuvastatin as cholesterol-reducing agents with improved anti-inflammatory, antithrombotic and antiplatelet activity |
Non-Patent Citations (3)
| Title |
|---|
| AEJIN KIM, ET AL.,: "A Catalytic Approach to the Synthesis of (+)-Fluvastatin Analogue.", 《BULL. KOREAN CHEM. SOC.》, vol. 32, no. 10, 31 December 2011 (2011-12-31), pages 3748 - 3751 * |
| BAHIA A. MOUSSA, ET AL.,: "Spectroscopic and chromatographic determination of fluvastatin sodium in presence of its acid degradate.", 《INTERNATIONAL JOURNAL OF PHARMTECH RESEARCH》, vol. 2, no. 1, 31 December 2010 (2010-12-31), pages 875 - 898 * |
| PETER C. FUENFSCHILLING, ET AL.,: "An Improved Manufacturing Process for Fluvastatin.", 《ORGANIC PROCESS RESEARCH & DEVELOPMENT》, vol. 11, 31 December 2007 (2007-12-31), pages 13 - 18 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105017231A (en) * | 2015-06-26 | 2015-11-04 | 上海应用技术学院 | Polysubstituted indole statin fluorine-containing modifier and use thereof |
| CN105017231B (en) * | 2015-06-26 | 2018-01-26 | 上海应用技术学院 | Polysubstituted fluorine-containing trim of indoles statin and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104327057B (en) | 2017-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104356118A (en) | Polysubstitution pyrroles pitavastatin lactone dewatering compound and application thereof | |
| CN102432663B (en) | Celastrol derivative and preparation method thereof and application of celastrol derivative to preparation of antitumor medicine | |
| CN104356119A (en) | Polysubstitution miazines pitavastatin lactone dewatering compound and application thereof | |
| CN109464675A (en) | A kind of preparation method and application of triptolide-carboxyl chitosan coupling drug | |
| CN105524033A (en) | Fumaric acid eutectic of dapagliflozin, and preparation method and pharmaceutical composition thereof | |
| Liu et al. | A drug–drug cocrystal of dihydromyricetin and pentoxifylline | |
| JP2011516588A (en) | Galantamine derivatives as prodrugs for the treatment of human brain disease | |
| CN105017231A (en) | Polysubstituted indole statin fluorine-containing modifier and use thereof | |
| CN104356120A (en) | Polysubstitution quinolines pitavastatin lactone dewatering compound and application thereof | |
| CN104327057A (en) | Poly-substituted indole statin lactone dehydrated compound and use thereof | |
| CN105017230A (en) | Polysubstituted quinoline derivative and use thereof | |
| CN103450163A (en) | Indazole compounds, preparation method, and pharmaceutical applications thereof | |
| CN105175399A (en) | Poly-substituted pyrimidine statin fluorine-containing derivative and uses thereof | |
| CN104311517A (en) | Polysubstituted phenanthrene ring statin lactone dehydrated compounds and application thereof | |
| AU2016214849B2 (en) | Compound, and separation method, synthesis method and use thereof | |
| Li et al. | Design, synthesis and lipid-lowering activities of penipyridone derivatives | |
| CN109675050A (en) | Using camptothecine as the conjugate and its preparation and application of the analog of parent nucleus and nonsteroidal anti-inflammatory drug | |
| CN105085497A (en) | Polysubstituted pyrrole statin fluorinated derivative and use thereof | |
| CN105111173A (en) | Poly-substituted phenanthrene ring statin fluorine-containing derivative and uses thereof | |
| CN104530029B (en) | Heterocyclic compounds as factor Xa inhibitors as well as using methods and application of heterocyclic compounds | |
| CN107224436B (en) | twin drug type HMG-CoA reductase inhibitor and synthesis method thereof | |
| CN102633796B (en) | New preparation method of sophora flavescens acid derivative | |
| CN102387799B (en) | Use of atorvastatin lactols as medicaments | |
| CN102757460B (en) | Dihydroartemisinin sesquioxide germanium compound and preparation method as well as application thereof | |
| CN104744451A (en) | 1-(3-amino propyl) substituted cyclic amine compound as well as preparation method, pharmaceutical composition and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170118 Termination date: 20191017 |